3 results
The primary objective of the study is to evaluate the efficacy of agomelatine (25-50 mg/day) compared to placebo on the reduction of Obsessive and Compulsive symptoms by using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) after 16 weeks of…
Phase 1b Dose Escalation Objectives • To determine the safety and tolerability of escalating doses of GB5121• To determine the optimal biological dose (OBD) and/or maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of GB5121 Phase 1b…
The purpose of this study is to investigate how quickly and to what extent branaplam is absorbed and eliminated from the body (this is called pharmacokinetics). Branaplam will be labelled with Carbon-14 (14C) and is thus radioactive. In this way…